Tegafur,Gimeracil and Oteracil Potassium
- Generic Name
- Tegafur,Gimeracil and Oteracil Potassium
- Indication
用于不能切除的局部晚期或转移性胃癌。
用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT06109779
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
- Conditions
- Adenocarcinoma of the StomachAdenocarcinoma of Esophagogastric JunctionEpstein-Barr Virus-Associated Gastric Carcinoma
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Yu jiren
- Target Recruit Count
- 30
- Registration Number
- NCT05970627
- Locations
- 🇨🇳
Ningbo First Hospital, Ningbo, Zhejiang, China
🇨🇳Ningbo Medical Center LiHuiLi Hospital, Ningbo, Zhejiang, China
🇨🇳The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
- Conditions
- Adenocarcinoma of the StomachProficient Mismatch RepairAdenocarcinoma of Esophagogastric Junction
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Yu jiren
- Target Recruit Count
- 314
- Registration Number
- NCT05872685
- Locations
- 🇨🇳
Lishui Central Hospital, Lishui, Zhejiang, China
🇨🇳The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Taizhou Hospital, Taizhou, Zhejiang, China
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Metastatic Solid TumorNon-small Cell Lung CancerGastric CancerPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05867121
- Locations
- 🇹🇷
Ege University Medical Faculty, Izmir, Turkey
🇹🇷Dokuz Eylul Universitesi Tip Fakultesi, Lzmir, Turkey
🇺🇸UCLA University of California Los Angeles, Los Angeles, California, United States
Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-05-10
- Target Recruit Count
- 30
- Registration Number
- NCT05853172
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma
- Conditions
- Biliary Tract Carcinoma
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05822453
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China
Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases
- Conditions
- For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 100
- Registration Number
- NCT05774964
- Locations
- 🇨🇳
Liaoning Tumor Hospital & Institute, Shenyang, Liaoning, China
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer
- Conditions
- Serplulimab,Gastric Cancer, Adjuvant Therapy
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05769725
- Locations
- 🇨🇳
Zhang Zizhen, Shanghai, China
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
- Conditions
- Adenocarcinoma of Esophagogastric JunctionAdenocarcinoma of the StomachMismatch Repair Deficiency
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Yu jiren
- Target Recruit Count
- 90
- Registration Number
- NCT05729646
- Locations
- 🇨🇳
The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Ningbo Second Hospital, Ningbo, Zhejiang, China
🇨🇳Ningbo Medical Center LiHuiLi Hospital, Ningbo, Zhejiang, China
Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection
- Conditions
- Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 100
- Registration Number
- NCT05720559
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.